Icon Plc (NASDAQ:ICLR) – Research analysts at Jefferies Financial Group issued their Q1 2020 EPS estimates for shares of Icon in a research note issued on Monday, January 21st. Jefferies Financial Group analyst D. Windley anticipates that the medical research company will post earnings per share of $1.82 for the quarter. Jefferies Financial Group also issued estimates for Icon’s Q2 2020 earnings at $1.85 EPS, Q3 2020 earnings at $1.86 EPS and Q4 2020 earnings at $1.90 EPS.

Icon (NASDAQ:ICLR) last announced its earnings results on Wednesday, October 24th. The medical research company reported $1.54 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $1.54. Icon had a net margin of 12.88% and a return on equity of 26.08%. The business had revenue of $655.02 million for the quarter, compared to analyst estimates of $654.66 million.

ICLR has been the topic of several other research reports. UBS Group set a $136.00 price target on shares of Icon and gave the company a “sell” rating in a report on Saturday, October 27th. Zacks Investment Research lowered shares of Icon from a “hold” rating to a “sell” rating in a report on Tuesday, January 8th. Evercore ISI raised shares of Icon from an “in-line” rating to an “outperform” rating in a report on Friday, October 26th. BidaskClub lowered shares of Icon from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 5th. Finally, Goldman Sachs Group lowered shares of Icon from a “conviction-buy” rating to a “buy” rating and set a $168.00 price target on the stock. in a report on Friday, December 14th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company. Icon presently has an average rating of “Buy” and a consensus price target of $152.67.

Shares of ICLR stock opened at $132.62 on Wednesday. Icon has a 1 year low of $101.22 and a 1 year high of $155.33. The firm has a market cap of $7.20 billion, a P/E ratio of 24.60, a P/E/G ratio of 1.70 and a beta of 0.67. The company has a debt-to-equity ratio of 0.26, a quick ratio of 2.17 and a current ratio of 2.17.

Institutional investors have recently made changes to their positions in the business. WCM Investment Management CA grew its holdings in shares of Icon by 7.9% in the 3rd quarter. WCM Investment Management CA now owns 5,000,711 shares of the medical research company’s stock worth $768,860,000 after purchasing an additional 367,131 shares during the last quarter. Clearbridge Investments LLC grew its holdings in shares of Icon by 9.8% in the 3rd quarter. Clearbridge Investments LLC now owns 2,211,986 shares of the medical research company’s stock worth $340,093,000 after purchasing an additional 198,271 shares during the last quarter. Acadian Asset Management LLC grew its holdings in shares of Icon by 0.4% in the 3rd quarter. Acadian Asset Management LLC now owns 2,181,795 shares of the medical research company’s stock worth $335,450,000 after purchasing an additional 8,880 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of Icon by 12.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,070,319 shares of the medical research company’s stock worth $164,561,000 after purchasing an additional 121,970 shares during the last quarter. Finally, Janus Henderson Group PLC grew its holdings in shares of Icon by 5.0% in the 3rd quarter. Janus Henderson Group PLC now owns 788,206 shares of the medical research company’s stock worth $121,140,000 after purchasing an additional 37,851 shares during the last quarter. 86.39% of the stock is currently owned by hedge funds and other institutional investors.

About Icon

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Featured Story: Tariff

Earnings History and Estimates for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.